News
Novo Nordisk Moves Delhi HC Against Dr Reddy’s Over Olymviq Brand
Delhi High Court pauses Olymviq rollout after Novo Nordisk argues the name is too close to Ozempic just days after semaglutide patent protection expired in India.
Delhi High Court pauses Olymviq rollout after Novo Nordisk argues the name is too close to Ozempic just days after semaglutide patent protection expired in India.
Credit ratings agency says capital-heavy sectors from utilities to pharma will see slower AI adoption while cloud, chips and data services emerge as winners.